Cefazolin
Ancef, Kefzol (cefazolin) is a small molecule pharmaceutical. Cefazolin was first approved as Ancef on 1982-01-01. It is used to treat bacterial endocarditis, bacterial infections, bacterial pneumonia, bacterial skin diseases, and escherichia coli infections amongst others in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefazolin sodium
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CEFAZOLIN AND DEXTROSE | B. Braun Medical | N-050779 RX | 2000-07-27 | 2 products, RLD, RS |
CEFAZOLIN IN PLASTIC CONTAINER | Baxter | N-207131 RX | 2015-08-07 | 2 products, RLD, RS |
CEFAZOLIN SODIUM | Hikma Pharmaceuticals | N-216109 RX | 2022-10-07 | 2 products, RLD, RS |
CEFAZOLIN SODIUM | HQ Specialty Pharma | N-211413 RX | 2023-05-08 | 1 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
cefazolin | ANDA | 2023-06-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
bacterial endocarditis | EFO_1000830 | D004697 | — |
bacterial infections | — | D001424 | A49 |
bacterial pneumonia | EFO_1001272 | D018410 | J15.9 |
bacterial skin diseases | — | D017192 | — |
escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
human bites | — | D001734 | W50.3 |
klebsiella infections | EFO_1001353 | D007710 | — |
proteus infections | EFO_1001130 | D011512 | — |
soft tissue infections | — | D018461 | — |
staphylococcal infections | — | D013203 | A49.01 |
Show 2 more
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
CEFAZOLIN SODIUM, CEFAZOLIN AND DEXTROSE, B BRAUN | |||
2023-11-23 | NPP |
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
J0690 | Injection, cefazolin sodium, 500 mg |
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
Infectious arthritis | D001170 | EFO_1001351 | M00 | 1 | — | — | — | — | 1 |
Pyomyositis | D052880 | EFO_1001409 | M60.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Mastitis | D008413 | EFO_1001034 | N61 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CEFAZOLIN |
INN | cefazolin |
Description | Cefazolin is a first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively. It has a role as an antibacterial drug. It is a cephalosporin, a member of thiadiazoles, a member of tetrazoles and a beta-lactam antibiotic allergen. It is a conjugate acid of a cefazolin(1-). |
Classification | Small molecule |
Drug class | cephalosporins |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1 |
Identifiers
PDB | — |
CAS-ID | 25953-19-9 |
RxCUI | 2180 |
ChEMBL ID | CHEMBL1435 |
ChEBI ID | 474053 |
PubChem CID | 33255 |
DrugBank | DB01327 |
UNII ID | IHS69L0Y4T (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 20,063 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
498 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more